• CEO, Dr James Garner’s presentation to H.C. Wainwright 22nd Annual Global Investment Conference watch here

Kazia is an Australian oncology company developing innovative, high-impact drugs for cancer. Our lead program is paxalisib, which is being developed to treat glioblastoma, the most common and most aggressive form of primary brain cancer in adults.